

---

**NEOPROBE TO PRESENT AT OPPENHEIMER HEALTHCARE CONFERENCE  
CEO To Provide Business Update**

DUBLIN, OHIO – October 27, 2009 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present on Wednesday, November 4th, 2009 at 4:30PM ET during the 20th Annual Oppenheimer Healthcare Conference to be held at the Waldorf Hotel in New York, New York. Mr. Bupp's presentation will provide an overview of the Company's technology and business strategy including information on its market-leading gamma surgery medical devices, a clinical results update on its Phase 3 radiopharmaceutical product, Lymphoseek<sup>®</sup>, a development update on RIGScan<sup>®</sup> CR and a discussion of the very recently invigorated clinical opportunities for its ACT technology.

Interested parties can access a live, or an archived internet audio broadcast of the presentation, along with accompanying slides, at:

<http://www.veracast.com/webcasts/opco/healthcare09/47214544.cfm>

The presentation will be archived for 90 days.

***About Neoprobe***

*Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe<sup>®</sup> GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek<sup>®</sup> and RIGScan<sup>®</sup> CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. [www.neoprobe.com](http://www.neoprobe.com)*